Business Wire

RSM and DSI Agree to Cross-Border Insolvency Strategic Alliance

Share

Two well-known and respected firms in the global restructuring industry have formed a strategic alliance and international collaboration to further support their respective clients amid a growing wave of cross-border insolvency and international restructuring projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190123005735/en/

U.K.-based restructuring practice RSM Restructuring Advisory LLP ("RSM"), part of audit, tax and consulting firm RSM UK, and U.S.-based restructuring firm Development Specialists, Inc. (DSI), have announced an agreement to collaborate and augment each respective firm's services in dealing with transnational cases.

"We're delighted to announce that we'll be collaborating with DSI on cross-border projects,” said Graham Bushby, a Partner and Head of Restructuring Advisory at RSM. “DSI is working on some significant transnational cases and brings a wealth of experience to the arena, which RSM can capably augment in countries outside the U.S. market."

Bill Brandt, Executive Chairman of DSI, along with Brad Sharp, its President and CEO, said this alliance should provide a big boost for their firm as bankruptcies and insolvencies are starting to play out on a larger stage.

“Corporations have become interconnected to many countries so that when one part of the business experiences financial problems, the ramifications are far reaching and complex,” said Brandt. “That is why having access to the resources of a group like RSM overseas will greatly enhance our business, and at the same time, they can benefit from our 45 years of restructuring experience in North America.”

“With more and more of our work becoming international, it made a lot of sense to re-establish a presence in Europe where we had operated for many years in the past,” said Sharp. “I look forward to a long and productive relationship with RSM and their team of outstanding restructuring professionals.”

About RSM UK:

RSM UK is a leading audit, tax and consulting firm to the middle market with nearly 3,500 partners and staff operating from 35 locations throughout the UK. For the year ending 31 March 2017, RSM generated revenues of £319m. RSM UK is a member firm of RSM International - the sixth largest network of audit, tax and consulting firms globally. The network spans over 120 countries, 800 offices and more than 43,000 people, with a fee income of more than $5bn.

About Development Specialist, Inc. (DSI):

DSI is a leading provider of management consulting and financial advisory services to companies in need of operational improvements, balance sheet restructuring or turnaround management. DSI excels due to the extensive experience and diverse background of its consultants. The team includes Masters of Professional Accountancy, Certified Public Accountants, Certified Insolvency and Restructuring Advisors, Certified Financial Forensic Accountants and Certified Internal Auditors. As one of the first turnaround firms in the U.S., DSI has expanded from its headquarters in Chicago to include a significant national footprint with offices in New York, Los Angeles, San Francisco, South Florida, Wilmington and Columbus, Ohio. For more information, visit www.dsi.biz.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries for RSM:
Ed Dewar, Senior PR Manager, 0203 201 8145
Frank Shepherd, PR Manager, 020 3201 8072
Gemma Moorhouse, PR Manager, 0113 285 5076

Media inquiries for DSI:
Todd Templin, 954-370-8999/954-290-0810
or
ttemplin@boardroompr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye